| BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX9930, an oral factor D inhibitor, which is in Phase II clinical trial for complement-mediated diseases; BCX9250, an oral activin receptor-like kinase-2 inhibitor that is in Phase I clinical trial to treat fibrodysplasia ossificans progressiva; and Galidesivir, a RNA dependent-RNA polymerase inhibitor, which is in Phase I clinical trial to treat various RNA viruses, including Marburg, Yellow Fever, Ebola, and Zika. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; Mundipharma International Holdings Limited; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina. |
| Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
| ABERCROMBIE GEORGE B | Director | Apr 18 | Option Exercise | 3.32 | 5,000 | 16,600 | 5,000 | Apr 20 04:23 PM | | ABERCROMBIE GEORGE B | Director | Apr 18 | Sale | 11.04 | 5,000 | 55,200 | 0 | Apr 20 04:23 PM | | Thackray Helen M. | Chief R&D Officer | Apr 01 | Sale | 16.20 | 7,600 | 123,120 | 136,400 | Apr 04 04:32 PM | | Sheridan William P | Chief Medical Officer | Mar 10 | Option Exercise | 3.22 | 148,302 | 477,532 | 199,093 | Mar 14 04:21 PM | | Sheridan William P | Chief Medical Officer | Mar 10 | Sale | 16.88 | 161,139 | 2,719,493 | 37,954 | Mar 14 04:21 PM | | Babu Yarlagadda S | Chief Discovery Officer | Mar 07 | Sale | 17.16 | 20,000 | 343,200 | 230,056 | Mar 09 04:24 PM | | Jones Michael L | Exec. Director, Finance - PAO | Mar 01 | Option Exercise | 4.73 | 2,300 | 10,879 | 13,498 | Mar 03 05:04 PM | | Jones Michael L | Exec. Director, Finance - PAO | Mar 01 | Sale | 17.20 | 2,300 | 39,560 | 11,198 | Mar 03 05:04 PM | | ABERCROMBIE GEORGE B | Director | Feb 15 | Option Exercise | 3.32 | 5,000 | 16,600 | 5,000 | Feb 16 04:25 PM | | ABERCROMBIE GEORGE B | Director | Feb 15 | Sale | 18.50 | 5,000 | 92,500 | 0 | Feb 16 04:25 PM | | Stonehouse Jon P | President & CEO | Jan 11 | Option Exercise | 4.73 | 184,000 | 870,320 | 1,085,602 | Jan 13 04:45 PM | | Stonehouse Jon P | President & CEO | Jan 11 | Sale | 15.04 | 184,000 | 2,767,360 | 901,602 | Jan 13 04:45 PM | | Babu Yarlagadda S | Chief Discovery Officer | Dec 07 | Option Exercise | 4.73 | 62,000 | 293,260 | 245,156 | Dec 09 04:38 PM | | Babu Yarlagadda S | Chief Discovery Officer | Dec 07 | Sale | 12.20 | 30,100 | 367,220 | 215,056 | Dec 09 04:38 PM | | MILANO VINCENT | Director | Nov 24 | Buy | 12.19 | 7,500 | 91,425 | 17,500 | Nov 24 06:35 PM | | Doyle Anthony | Chief Financial Officer | Nov 23 | Buy | 12.48 | 35,258 | 440,020 | 93,719 | Nov 24 06:35 PM | | ABERCROMBIE GEORGE B | Director | Nov 15 | Option Exercise | 3.32 | 5,000 | 16,600 | 5,000 | Nov 17 04:27 PM | | ABERCROMBIE GEORGE B | Director | Nov 15 | Sale | 12.27 | 5,000 | 61,350 | 0 | Nov 17 04:27 PM | | Hutson Nancy J | Director | Oct 15 | Option Exercise | 3.46 | 105,000 | 363,450 | 170,073 | Oct 19 04:21 PM | | Hutson Nancy J | Director | Oct 15 | Sale | 15.40 | 105,000 | 1,617,000 | 65,073 | Oct 19 04:21 PM | | ABERCROMBIE GEORGE B | Director | Sep 15 | Option Exercise | 2.63 | 5,000 | 13,150 | 5,000 | Sep 17 04:31 PM | | ABERCROMBIE GEORGE B | Director | Sep 15 | Sale | 15.06 | 5,000 | 75,300 | 0 | Sep 17 04:31 PM | | LEE KENNETH B JR | Director | Sep 13 | Option Exercise | 3.22 | 15,000 | 48,300 | 30,252 | Sep 15 04:26 PM | | LEE KENNETH B JR | Director | Sep 13 | Sale | 15.35 | 6,000 | 92,100 | 24,252 | Sep 15 04:26 PM | | ABERCROMBIE GEORGE B | Director | Sep 10 | Option Exercise | 2.86 | 71,000 | 202,710 | 74,000 | Sep 14 04:14 PM | | ABERCROMBIE GEORGE B | Director | Sep 10 | Sale | 15.09 | 74,000 | 1,116,660 | 0 | Sep 14 04:14 PM | | ABERCROMBIE GEORGE B | Director | Jul 15 | Option Exercise | 2.63 | 5,000 | 13,150 | 8,000 | Jul 19 04:39 PM | | ABERCROMBIE GEORGE B | Director | Jul 15 | Sale | 15.69 | 5,000 | 78,450 | 3,000 | Jul 19 04:39 PM | | Hutson Nancy J | Director | Jun 10 | Option Exercise | 3.15 | 23,333 | 73,549 | 88,406 | Jun 14 04:29 PM | | Hutson Nancy J | Director | Jun 10 | Sale | 16.86 | 23,333 | 393,394 | 65,073 | Jun 14 04:29 PM | | Sheridan William P | Chief Medical Officer | May 28 | Option Exercise | 5.38 | 91,814 | 493,826 | 106,289 | Jun 01 04:33 PM | | Sheridan William P | Chief Medical Officer | May 28 | Sale | 15.02 | 91,814 | 1,379,046 | 14,475 | Jun 01 04:33 PM | | Sheridan William P | Chief Medical Officer | May 27 | Option Exercise | 5.27 | 71,759 | 378,114 | 86,234 | Jun 01 04:33 PM | | Sheridan William P | Chief Medical Officer | May 27 | Sale | 15.00 | 71,759 | 1,076,385 | 14,475 | Jun 01 04:33 PM |
|
